|
Synonyms: IMO-2125 | IMO2125
Compound class:
Nucleic acid
Comment: Tilsotolimod (IMO-2125) is a phosphorothioate (P-thio) CpG oligonucleotide that is intended to act as a Toll-like receptor 9 (TLR9) agonist. Structurally it is a symmetrical, dual-strand 3'-3'-linked molecule.
Full sequence is : O,O'-(2-hydroxypropane-1,3-diyl) bis(hydrogen all-P-ambo-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thio-3'-guanylate) |
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04126876 | A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | Phase 2 Interventional | Amsterdam UMC, location VUmc | ||
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | Phase 3 Interventional | Idera Pharmaceuticals, Inc. | The ILLUMINATE-301 study | 1 |